Incidence of herpes labialis during use of the preventative intervention ‐ presurgical · participants with recurrent herpes labialis
Interferon may leads to higher incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Incidence of herpes labialis during use of the preventative intervention ‐ pre‐ and postsurgical · participants with recurrent herpes labialis
Interferon may leads to lower incidence of herpes labialis during use of the preventative… compared with placebo (low certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ presurgical · participants with recurrent herpes labialis
Interferon probably leads to higher adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects during use of the preventative intervention (fever) ‐ pre‐ and postsurgical · participants with recurrent herpes labialis
Interferon showed no clear difference in adverse effects during use of the preventative intervention (fever)… compared with placebo (moderate certainty).
1 finding from 1 review
Overall survival (OS) · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (ORR), · stage III and IV cutaneous melanoma
It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).
1 finding from 1 review
Time to recurrence ‐ not measured · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not reported · stage III and IV cutaneous melanoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found